Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by HighSkies2019 on Nov 27, 2020 4:21pm

New NR

Hey Moonshine .... there are 4 or 5 nr ....Q3 and MD&A ..... but I cant get them open today ..... anyone else with that issue..... I would like to look over the md&a ... thx if anyone can bring over a print or link
Comment by Moonshiner592 on Nov 27, 2020 4:41pm
... I just saw them .. I was able to open them ... looks like we're getting some progress here...finally! GLTA
Comment by ETalien on Nov 27, 2020 7:37pm
Sorry, I just came on board... I read most of it.. and with each line I read...my blood heated up to the boiling point. That is why wrote what I thought.  it's very discouraging!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities